Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-400 |
Synonyms | |
Therapy Description |
ABBV-400 is an antibody-drug conjugate (ADC) comprising an anti-MET monoclonal antibody conjugated to a topoisomerase inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 6311). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-400 | ABBV 400|ABBV400 | MET Antibody 29 | ABBV-400 is an antibody-drug conjugate (ADC) comprising an anti-MET monoclonal antibody conjugated to a topoisomerase inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 6311). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | FRA | ESP | AUS | 6 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | 5 |